Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585196 | 0.82 | NPC1 (0.42) | TAAR1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL1178776 | 0.81 | HTT (0.59) | TAAR1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL28486525 | 0.80 | MEN1 (0.49) | SMN1; SMN2KMT2AKDM4EL3MBTL1TSHR | |
| SCHEMBL28482356 | 0.77 | MEN1 (0.51) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL28477887 | 0.76 | MAPT (0.45) | KMT2AHIF1AL3MBTL1MEN1LMNA | |
| SCHEMBL13744614 | 0.75 | NPC1 (0.56) | TAAR1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL28762492 | 0.74 | NPC1 (0.71) | TAAR1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL14454238 | 0.74 | RAB9A (0.81) | TAAR1RAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL6072210 | 0.73 | HIF1A (0.59) | RAB9ANPC1SMN1; SMN2KDM4EKDM5A | |
| SCHEMBL30131466 | 0.73 | KMT2A (0.69) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028452-A1 | PYRIDO[4,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2011-02-03 | — | — | US | disclosed |
| US-20110028452-A1 | PYRIDO[4,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2011-02-03 | — | — | US | disclosed |
| US-20110028452-A1 | PYRIDO[4,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2011-02-03 | — | — | US | disclosed |
| US-7829572-B2 | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists | PFIZER INC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829572-B2 | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists | PFIZER INC (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829572-B2 | Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists | PFIZER INC (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2079739-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER INC | 2008-04-10 | — | — | US | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008041118-A2 | PYRIDO[4,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085887-A1 | PYRIDO [4,3-d] PYRIMIDIN-4 (3H) -ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PTH1R, VDR, P2RY1 | TAAR1 762/4885RAB9A 1225/4885NPC1 4546/4885 |
| US-20110028452-A1 | PYRIDO[4,3-d]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS | PTH1R, VDR, P2RY1 | TAAR1 762/4885RAB9A 1225/4885NPC1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.